Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Bullish +75

Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits

Clinical trial results Drug approval AI-generated analysis

πŸ“ˆ Edwards Lifesciences' PASCAL system met its six-month primary endpoint in the CLASP IITR trial, with treated patients nearly twice as likely to benefit compared to medical therapy alone.

πŸ’Š Quality of life improvements were the main driver for the PASCAL trial, with 57% of device-treated patients achieving moderate-to-large KCCQ score improvements versus 25% in the control group.

πŸ₯ At one year follow-up, 80% of PASCAL patients achieved moderate or less tricuspid regurgitation compared to just 30% of patients receiving optimal medical therapy alone.

❀️ The PROGRESS trial demonstrated that TAVR reduced the two-year risk of death or heart-failure events by 33% in high-risk patients with moderate aortic stenosis.

πŸ₯ Heart-failure hospitalizations were reduced by 52% among patients treated with TAVR in the PROGRESS study, significantly improving patient outcomes over clinical surveillance.

πŸ”¬ Edwards Lifesciences highlighted that tricuspid regurgitation remains underdiagnosed, and the PASCAL data supports earlier intervention for symptomatic patients.

πŸ“Š The ACTIVATE analysis revealed that 80% of moderate aortic stenosis patients had at least one high-risk feature, suggesting many may benefit from TAVR despite current approval limitations.

🀝 Both the CLASP IITR and PROGRESS trials were designed in collaboration with the FDA to evaluate specific patient populations for potential future label expansions.

Bullish Signals
  • Edwards Lifesciences' PASCAL system met its six-month primary endpoint, with treated patients nearly twice as likely to experience a composite benefit compared to medical therapy alone.
  • The CLASP IITR trial showed that 57% of device-treated patients achieved moderate-to-large improvements in quality of life scores, significantly outperforming the 25% improvement rate in the control group.
  • At one year, 80% of PASCAL patients maintained moderate or less tricuspid regurgitation compared to only 30% of controls, demonstrating sustained efficacy in valve repair.
  • The PROGRESS trial found that TAVR reduced the two-year risk of death or heart-failure events by 33% in high-risk patients with moderate aortic stenosis.
  • Edwards Lifesciences' TAVR treatment resulted in a 52% reduction in heart-failure hospitalizations, primarily driving the overall benefit observed in the PROGRESS study.
  • The ACTIVATE analysis indicated that 80% of moderate aortic stenosis patients had at-risk features, highlighting a large potential patient population for Edwards' TAVR technology.
Full Analysis
Edwards Lifesciences (NYSE:EW) presented new clinical data demonstrating significant patient benefits from its PASCAL and TAVR programs. The CLASP IITR trial for the PASCAL transcatheter edge-to-edge repair system met its six-month primary endpoint, showing treated patients were nearly twice as likely to experience a composite benefit compared to those receiving medical therapy alone. The primary driver of this improvement was enhanced quality of life, measured by KCCQ scores, with 57% of device-treated patients achieving moderate-to-large improvements versus 25% in the control group. At one year, 80% of PASCAL patients maintained moderate or less tricuspid regurgitation compared to only 30% of controls, indicating sustained efficacy in managing severe tricuspid regurgitation. Additionally, Edwards highlighted the PROGRESS trial evaluating TAVR in patients with moderate aortic stenosis and high-risk features. The study found that TAVR reduced the two-year risk of death or heart-failure events by 33%, primarily driven by a 52% reduction in heart-failure hospitalizations. While these findings suggest potential for label expansion, Edwards noted that moderate aortic stenosis is not yet an approved indication and no timeline was provided. The data reinforces Edwards' position as a leader in structural heart disease therapies, addressing underdiagnosed conditions like tricuspid regurgitation and redefining the management of moderate aortic stenosis. Executives emphasized that these trials were designed in collaboration with the FDA to assess patient populations previously considered for surveillance rather than intervention.